ClearArc Capital’s Quest Diagnostics DGX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q4
Sell
-2,029
Closed -$217K 316
2019
Q3
$217K Buy
2,029
+18
+0.9% +$1.85K 0.06% 332
2019
Q2
$205K Sell
2,011
-229
-10% -$22K 0.06% 343
2019
Q1
$201K Buy
+2,240
New +$194K 0.05% 368
2018
Q4
Sell
-3,517
Closed -$380K 369
2018
Q3
$380K Buy
3,517
+18
+0.5% +$1.97K 0.05% 340
2018
Q2
$385K Buy
3,499
+30
+0.9% +$3.13K 0.05% 321
2018
Q1
$348K Buy
3,469
+11
+0.3% +$1.13K 0.05% 353
2017
Q4
$341K Sell
3,458
-57
-2% -$5.4K 0.05% 357
2017
Q3
$329K Buy
3,515
+143
+4% +$15.2K 0.05% 353
2017
Q2
$375K Buy
3,372
+24
+0.7% +$2.54K 0.06% 305
2017
Q1
$329K Sell
3,348
-13
-0.4% -$1.24K 0.05% 334
2016
Q4
$309K Sell
3,361
-50
-1% -$4.31K 0.06% 338
2016
Q3
$289K Sell
3,411
-45
-1% -$3.78K 0.05% 347
2016
Q2
$281K Sell
3,456
-16
-0.5% -$1.22K 0.05% 347
2016
Q1
$248K Sell
3,472
-572
-14% -$38.4K 0.05% 374
2015
Q4
$288K Sell
4,044
-6,928
-63% -$466K 0.06% 336
2015
Q3
$674K Sell
10,972
-63
-0.6% -$4.4K 0.14% 190
2015
Q2
$800K Sell
11,035
-3,422
-24% -$253K 0.15% 181
2015
Q1
$1.11M Buy
14,457
+2,068
+17% +$148K 0.23% 123
2014
Q4
$831K Buy
+12,389
New +$782K 0.17% 162

Other funds holding DGX

ClearArc Capital's DGX Position: Q4 2019 in Review

ClearArc Capital sold out of Quest Diagnostics (DGX) in Q4 2019, closing a stake of 2,029 shares — an estimated $217K sold.

ClearArc Capital first reported a position in DGX in Q4 2014 and held it in 19 quarters. The position peaked at $1.11M in Q1 2015. 712 funds tracked by Wall St. Rank hold DGX as of Q4 2019.

  • ClearArc Capital reported no remaining Quest Diagnostics position as of Q4 2019 after selling out during the quarter.
  • ClearArc Capital sold 2,029 Quest Diagnostics shares in Q4 2019, an estimated $217K.
  • ClearArc Capital first reported a position in Quest Diagnostics in Q4 2014 and held it in 19 quarters.
  • ClearArc Capital's Quest Diagnostics position peaked at $1.11M in Q1 2015.
  • 712 funds tracked by Wall St. Rank held Quest Diagnostics as of Q4 2019.

Based on ClearArc Capital's 13F filing for Q4 2019, filed 14 Feb 2020.